Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day

Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape of many solid tumors. Our review aims to summarize the main findings regarding the clinic...

Full description

Bibliographic Details
Main Authors:	Brigida Anna Maiorano, Ugo De Giorgi, Davide Ciardiello, Giovanni Schinzari, Antonio Cisternino, Giampaolo Tortora, Evaristo Maiello
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Biomedicines
Subjects:	urothelial carcinoma bladder cancer mUC BCa ICI immune checkpoint inhibitor
Online Access:	https://www.mdpi.com/2227-9059/10/2/411

Similar Items

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
by: Brigida Anna Maiorano, et al.
Published: (2021-06-01)

Anti-PD-1 immunotherapy for the treatment of metastatic urothelial carcinoma in a kidney transplant recipient: a case report
by: Houfeng Huang, et al.
Published: (2024-10-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)

Editorial: Radical cystectomy in bladder cancer patients
by: Vadim S. Koshkin, et al.
Published: (2022-12-01)

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience
by: Paola Parente, et al.
Published: (2022-03-01)

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
by: Brigida Anna Maiorano, et al.
Published: (2022-04-01)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
by: Brigida Anna Maiorano, et al.
Published: (2023-09-01)

Editorial: Identifying novel biomarkers in bladder cancer
by: Thorsten H. Ecke, et al.
Published: (2023-07-01)

Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review
by: Wang He, et al.
Published: (2023-07-01)

Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort
by: Anke Richters, et al.
Published: (2024-01-01)

Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma
by: Brigida Anna Maiorano, et al.
Published: (2024-05-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
by: Dietrich B, et al.
Published: (2018-01-01)

Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder
by: Hong-Lin He, et al.
Published: (2023-02-01)

The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis
by: Qiuqiu Qiu, et al.
Published: (2022-11-01)

Synchronous primary tumors of the bladder: Successfully managed case
by: Farah Boutaggount, MD, et al.
Published: (2022-10-01)

Profile of Lesions in Cystoscopic Bladder Biopsies: A Histopathological Study
by: Srikousthubha, et al.
Published: (2013-08-01)

Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
by: Sarah E. Fenton, et al.
Published: (2023-01-01)

Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in bladder urothelial carcinoma
by: Xiaobin Chen, et al.
Published: (2024-11-01)

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma
by: Huiyang Yuan, et al.
Published: (2023-05-01)

Comprehensive Analysis of CPA4 as a Poor Prognostic Biomarker Correlated with Immune Cells Infiltration in Bladder Cancer
by: Chengcheng Wei, et al.
Published: (2021-11-01)

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)

Urothelial carcinoma arising within bladder diverticulum—Report of a case and review of the literature
by: Hung-En Chen, et al.
Published: (2016-09-01)

A histopathologic study of urinary bladder tumors at tertiary care center in Mid-Western region of Nepal
by: Binita Goyal, et al.
Published: (2018-10-01)

Hematuria in a 12-year-old child, a rare case of urothelial papilloma of the urinary bladder
by: Alexis Litchinko, et al.
Published: (2016-04-01)

Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis
by: Esin Kaymaz, et al.
Published: (2017-01-01)

Histopathology of urinary bladder carcinoma: Less common variants
by: Damjanov Ivan, et al.
Published: (2011-01-01)

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction
by: Fuguang Zhao, et al.
Published: (2020-12-01)

The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: A prospective study
by: Min-Gu Park, et al.
Published: (2012-10-01)

Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer
by: George J. Dugbartey, et al.
Published: (2024-02-01)

Mucinous urothelial carcinoma of the renal pelvis
by: Kemal Behzatoğlu, et al.
Published: (2014-12-01)

Expression of Vitamin D Receptor (VDR) in Urinary Bladder Carcinoma: Immunohistochemical and Histopathological Study
by: Rehab Mohamed Sharaf, et al.
Published: (2022-09-01)

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
by: Ranferi Ocaña-Guzmán, et al.
Published: (2023-08-01)

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01)

Advances in molecular mechanism of bladder detrusor dysfunction
by: LIU Sheng-lai, TIAN Da-wei, WU Chang-li
Published: (2022-10-01)

Orbital Metastasis from Urothelial Carcinoma of the Urinary Bladder
by: Han-Ching Lin, et al.
Published: (2007-02-01)

A multidimensional analysis of the impact of obesity on immune checkpoint inhibitor therapy efficacy
by: Wenjing Xu, et al.
Published: (2024-10-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
by: Chao Xu, et al.
Published: (2023-05-01)

Diagnosis and management of intradiverticular bladder tumours: A pooled analysis of 498 cases
by: Stamatios Katsimperis, et al.
Published: (2022-12-01)